Obesity Drugs Spark Debate as Medicare Refuses Coverage for Promising New Treatments

Washington (AP)— The FDA has approved Zepbound, a weight-loss treatment developed from Mounjaro, a diabetes medication. Zepbound is lauded for its ability to help obese people lose weight. Due to Medicare’s refusal to cover promising injections like Zepbound and Wegovy, they have sparked a heated discussion. Drugmakers and a bipartisan coalition of lawmakers are passionately campaigning for Medicare coverage of these new treatments.

Obesity Drugs Spark Debate as Medicare Refuses Coverage for Promising New Treatments (Photo: Google)

The Dilemma of Medicare Coverage

Obscured behind the promising results of new obesity drugs lies an insurmountable obstacle for millions of older Americans – Medicare’s steadfast prohibition against covering such medications.

With obesity rates soaring among older adults, the contentious debate gains potency as lawmakers challenge the decades-old law that prevents Medicare from bearing the burden of new weight-loss drugs, including the highly acclaimed Zepbound and Wegovy.

Nevertheless, the staggering initial cost of covering these medications threatens to strain Medicare’s already precarious financial status, igniting a fierce conflict over the extension of Medicare’s coverage to include obesity drugs.

READ ALSO: Department Of Health And Human Services Of Maine Extends Deadline For SNAP Beneficiaries To Seek Assistance In Food Replacement

The Food and Drug Administration’s recent approvals of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound signify a revolutionary development in the treatment of obesity.

These weekly injectables have demonstrated the potential to facilitate weight loss ranging from 15% to 25% of body weight by replicating the functions of appetite-regulating hormones, which facilitate the communication of fullness between the gut and brain during meals.

Despite their efficacy, the exorbitant price tags associated with these drugs have been a significant barrier, rendering them accessible primarily to wealthier individuals. Moreover, shortages and stringent restrictions imposed by private insurers have further limited access to these pioneering treatments.

READ ALSO: Akido Street Medicine Team: Bringing Healthcare To Kern’s Rural Homeless, A Glimmer Of Hope Amid Neglect And Desolation